益气解毒通络颗粒对乙肝肝硬化患者肝星状细胞标记物VEGF和PDGF-AB的影响  

Effects of Yiqi Jiedu Tongluo Granules on VEGF and PDGF-AB in Patients with Post-Hepatitis B Liver Cirrhosis

作　　者：赫伟丽[1] 苑晓晨[2] 赵帆[1] 徐光福[1] 张爱军 He Weili;Yuan Xiaochen;Zhao Fan;Xu Guangfu;Zhang Aijun(Dongzhiment Hospital,Beijing University of Chinse Medicine,Beijing 100700,China)

机构地区：[1]北京中医药大学东直门医院,北京100700 [2]中国医学科学院&北京协和医学院微循环研究所,北京100005

出　　处：《世界中医药》2018年第11期2715-2720,共6页World Chinese Medicine

基　　金：2015年北京中医药校级课题(2015-JYB-JSMS085)

摘　　要：目的:探讨益气解毒通络颗粒剂治疗乙肝肝硬化好转的分子机制,完善该方治疗乙肝肝硬化的理论基础。方法:选取2015年6月至2017年10月在北京中医药大学东直门医院,采用简单随机化分组方法,随机选择符合入排标准的体检中心体检健康者15例,肝炎门诊就诊的乙肝肝硬化患者42例。乙肝肝硬化患者均已规范使用抗病毒药恩替卡韦分散片治疗,入组后予益气解毒通络颗粒治疗6个月;对健康者,乙肝肝硬化患者治疗前、治疗6个月后,分别采集血样,待标本集中后采用酶联免疫吸附法成批检测VEGF、PDGF-AB含量。并将测定结果进行统计分析。结果:结果显示,血清VEGF水平乙肝肝硬化患者治疗前较健康者轻度升高,治疗后较治疗前及健康者均有所下降,但组间比较无统计学意义(P>0. 05);血清PDGF-AB水平乙肝肝硬化患者治疗前较健康者显著降低(P <0. 001),治疗后较治疗前有所升高(P <0. 05)但仍低于健康者(P <0. 05)。结论:VEGF和PDGF-AB水平的变化与乙肝后肝硬化的发病相关,益气解毒通络颗粒能够改善乙肝肝硬化患者血清VEGF和PDGF-AB水平,这可能是其治疗乙肝肝硬化的作用机制之一。Objective：To discuss the molecular mechanisnl of Yiqi Jiedu Tongluo Granules, which was used for treating patients with post-hepatitis B liver cirrhosis, and to provide the theory foundation for it. Methods ： Cases were randomly selected from the visitors in Dongzhimen Hospital from June 2015 to October 2017 with 15 healthy persons of Medical Examination Center, and 42 patients with post-hepatitis B liver cirrhosis of Hepatitis clinic. The patients with post-hepatitis B liver cirrhosis had been treated by entecavir. The patients were treated with Yiqi Jiedu Tongluo Granules for 6 months ; The serum of the healthy persons, the patients before treatment,and the patients after treatment was collected. The method of ELISA was used to detect the serum level of VEGF and PDGF-AB. Results： The serum level of VEGF in patients with post-hepatitis B liver cirrhosis was increased than those of healthy persons, and after-treating was decreased than before-treating. But the level of VEGF was not statistically significant among groups （ P 〉 0. 05 ）. The serum level of PDGF-AB in patients with post-hepatitis B liver cirrhosis was significantly decreased than those of healthy persons （ P 〈 0. 001 ） ; after-treating was increased than before-treating （ P 〈 0. 05 ）, but was lower than those of healthy persons （P 〈 0. 05）. Conclusion：The serum level of VEGF and PDGF-AB has some relativity with post-hepatitis B liver cirrhosis. Yiqi Jiedu Tongluo Granules can affect the serum level of VEGF and PDGF-AB, which may be one of its treatment mechanisms.

关 键 词：益气解毒通络颗粒 乙肝肝硬化 毒损肝络 气虚络闭型 益气解毒通络法 肝星状细胞 血管内皮生长因子 血小板衍生生长因子 血小板衍生生长因子-AB 

分 类 号：R256.4[医药卫生—中医内科学]